Arginine and Asymmetric Dimethylarginine in Puromycin Aminonucleoside-Induced Chronic Kidney Disease in the Rat | Zendy

GinFu Chen | Zendy; Natasha C. Moningka | Zendy; Jennifer M. Sasser | Zendy; Sergey Zharikov | Zendy; Mark Cunningham | Zendy; YouLin Tain | Zendy; Idit F. Schwartz | Zendy; Chris Baylis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Arginine and Asymmetric Dimethylarginine in Puromycin Aminonucleoside-Induced Chronic Kidney Disease in the Rat

Author(s) -

GinFu Chen,

Natasha C. Moningka,

Jennifer M. Sasser,

Sergey Zharikov,

Mark Cunningham,

YouLin Tain,

Idit F. Schwartz,

Chris Baylis

Publication year - 2011

Publication title -

american journal of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 85

eISSN - 1421-9670

pISSN - 0250-8095

DOI - 10.1159/000334740

Subject(s) - asymmetric dimethylarginine , medicine , arginine , kidney disease , endocrinology , puromycin , disease , kidney , biochemistry , biology , amino acid , protein biosynthesis

Reduced renal L-arginine (L-Arg) synthesis/transport, induction of arginases and increased endogenous NOS inhibitor, asymmetric dimethylarginine (ADMA) will inhibit NO production. This study investigated pathways of L-Arg synthesis/uptake/utilization, ADMA degradation and oxidant/antioxidants in puromycin aminonucleoside (PAN) chronic kidney disease (CKD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research